Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: Using response to therapy variables to modify the initial risk estimates predicted by the new American thyroid association staging system

Thyroid

Volumn 20, Issue 12, 2010, Pages 1341-1349

  Tuttle, R Michael ^a   Tala, Hernan ^a   Shah, Jatin ^a   Leboeuf, Rebecca ^a   Ghossein, Ronald ^a   Gonen, Mithat ^a   Brokhin, Matvey ^a   Omry, Gal ^a   Fagin, James A ^a   Shaha, Ashok ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOACTIVE IODINE; THYROGLOBULIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; DISEASE CLASSIFICATION; DISEASE DURATION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; THYROID FOLLICLE CELL; THYROIDECTOMY; TREATMENT RESPONSE;

HUMANS; IODINE RADIOISOTOPES; NEOPLASM STAGING; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; THYROGLOBULIN; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 78649701492     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2010.0178     Document Type: Article

References (27)

1. Hay ID 2007 Management of patients with low-risk papillary thyroid carcinoma. Endocr Pract 13:521-533.
2. Mazzaferri EL 2007 Management of low-risk differentiated thyroid cancer. Endocr Pract 13:498-512.
3. Shaha AR, Shah JP, Loree TR 1997 Low-risk differentiated thyroid cancer: the need for selective treatment. Ann Surg Oncol 4:328-333.
4. Tuttle RM 2008 Risk-adapted management of thyroid cancer. Endocr Pract 14:764-774.
5. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167-1214.
6. Byar DP, Green SB, DorP, Williams ED, ColonJ,van Gilse HA, Mayer M, Sylvester RJ, van Glabbeke M 1979 A prognostic index forthyroid carcinoma.Astudyofthe E.O.R.T.C. Thyroid Cancer Cooperative Group. Eur J Cancer 15:1033-1041.
7. Lang BH, Lo CY, Chan WF, Lam KY, Wan KY 2007 Staging systems for papillary thyroid carcinoma: a review and comparison. Ann Surg 245:366-378.
8. Brierley JD, Panzarella T, Tsang RW, Gospodarowicz MK, O'Sullivan B 1997 A comparison of different staging systems predictability of patient outcome. Thyroid carcinoma as an example. Cancer 79:2414-2423.
9. Sherman SI, Brierley JD, Sperling M, Ain KB, Bigos ST, Cooper DS, Haugen BR, Ho M, Klein I, Ladenson PW, Robbins J, Ross DS, Specker B, Taylor T, Maxon HR, 3rd 1998 Prospective multicenter study of thyroid carcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer 83:1012-1021.
10. Verburg FA, Mader U, Kruitwagen CL, Luster M, Reiners C 2010 A comparison of prognostic classification systems for differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 72:830-838.
11. Shah JP 2008 Exploiting biology in selecting treatment for differentiated cancer of the thyroid gland. Eur Arch Otor-hinolaryngol 265:1155-1160.
12. Shaha AR, Shah JP, Loree TR 1996 Risk group stratification and prognostic factors in papillary carcinoma of thyroid. Ann Surg Oncol 3:534-538.
13. Castagna MG, Brilli L, Pilli T, Montanaro A, Cipri C, Fioravanti C, Sestini F, Capezzone M, Pacini F 2008 Limited value of repeat recombinant human thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH-stimulated thyroglobulin and undetectable basal serum thyroglobulin levels. J Clin Endocrinol Metab 93:76-81.
14. Chiovato L, Latrofa F, Braverman LE, Pacini F, Capezzone M, Masserini L, Grasso L, Pinchera A 2003 Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann Intern Med 139:346-351.
15. Kloos RT, Mazzaferri EL 2005 A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. J Clin Endocrinol Metab 90:5047-5057.
16. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, Haugen BR, Sherman SI, Cooper DS, Braunstein GD, Lee S, Davies TF, Arafah BM, Ladenson PW, Pinchera A 2003 A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 88:1433-1441. (Pubitemid 36623351)
17. Spencer CA 2000 Serum thyroglobulin measurements: clinical utility and technical limitations in the management of patients with differentiated thyroid carcinomas. Endocr Pract 6:481-484.
18. Toubeau M, Touzery C, Arveux P, Chaplain G, Vaillant G, Berriolo A, Riedinger JM, Boichot C, Cochet A, Brunotte F 2004 Predictive value for disease progression of serum thy-roglobulin levels measured in the postoperative period and after (131)I ablation therapy in patients with differentiated thyroid cancer. J Nucl Med 45:988-994.
19. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, Caillou B, Ricard M, Lumbroso JD, De Vathaire F, Schlumberger M 2006 Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 91:2892-2899.
20. Pacini F, Molinaro E, Castagna MG, Agate L, Elisei R, Ceccarelli C, Lippi F, Taddei D, Grasso L, Pinchera A 2003 Recombinant human thyrotropin-stimulated serum thyro-globulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 88:3668-3673.
21. Robbins RJ, Wan Q, Grewal RK, Reibke R, Gonen M, Strauss HW, Tuttle RM, Drucker W, Larson SM 2006 Realtime prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 91:498-505.
22. Nagelkerke NJD 1991 A note on a general definition of the coefficient of determination. Biometrika 78:691-692.
23. SAS Institute I 2002-2004 SAS 9.1.3 Help and Documentation, SAS Institute, Inc., Cary, NC.
24. Baek SK, Jung KY, Kang SM, Kwon SY, Woo JS, Cho SH, Chung EJ 2010 Clinical risk factors associated with cervical lymph node recurrence in papillary thyroid carcinoma. Thyroid 20:147-152.
25. Orlov S, Orlov D, Shaytzag M, Dowar M, Tabatabaie V, Dwek P, Yip J, Hu C, Freeman JL, Walfish PG 2009 Influence of age and primary tumor size on the risk for residual/recurrent well-differentiated thyroid carcinoma. Head Neck 31:782-788.
26. Mazzaferri EL, Kloos RT 2001 Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 86:1447-1463.
27. Knauf JA, Fagin JA 2009 Role of MAPK pathway oncopro-teins in thyroid cancer pathogenesis and as drug targets. Curr Opin Cell Biol 21:296-303.